# CARDIFF ONCOLOGY, INC. (CRDF) · Edgar & Edgarette company card

> Cardiff Oncology (CRDF) saw revenue fall 13.2% in FY2025 to $1 million, operating margin -8256% against a -15.8% median for biological products, (no diagnostic substances), equity 73.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1213037 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CRDF) · [JSON](https://www.pops4.com/boards/company/CRDF.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $593,000 |
| Revenue growth, 1 year | -13.2% |
| Revenue growth per year | 13.4% |
| Operating margin | -8256.3% (prior year -7123.1%) |
| Net margin | -7732.0% |
| Operating cash flow | −$38M |
| Capital spending | $44,000 |
| Free cash flow | −$38M |
| Cash | $17M |
| Long-term debt | — |
| Total assets | $62M |
| Total equity | $45M |
| Equity ÷ assets | 73.3% |
| Return on equity | -101.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -20.45 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$37.9M in FY2025); operating loss: a margin of -8256.3% in FY2025; revenue is hard to predict: its 80% range is ±45%

## Edgarette's reading

Exposure: revenue $593K (FY2025). Experience: revenue down 13.2% on the year, up 13.4% a year over 4 years; operating margin -8256.3%, down from -7123.1%. Soundness: equity 73.3% of assets, return on equity -101.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $361K and $955K next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $338K to $1.0M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -8256.3% against a -15.8% median; growth -13.2% against 21.4%.

Range logged 2026-10-09, receipt c14e3dc705ca9403, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-10-27 ([filing](https://www.sec.gov/Archives/edgar/data/1213037/000149315226048720/0001493152-26-048720-index.htm))

## Recent filings

- 8-K · filed 2026-11-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1213037/000119312526458500/0001193125-26-458500-index.htm)
- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/1213037/000119312526458485/0001193125-26-458485-index.htm)
- 8-K · filed 2026-10-27 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1213037/000149315226048720/0001493152-26-048720-index.htm)
- 8-K · filed 2026-10-22 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1213037/000149315226048111/0001493152-26-048111-index.htm)
- 8-K · filed 2026-09-14 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1213037/000149315226042506/0001493152-26-042506-index.htm)
- DEF 14A · filed 2026-08-26 · [filing](https://www.sec.gov/Archives/edgar/data/1213037/000119312526368249/0001193125-26-368249-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001213037.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1213037

## Cite

POPS4, Edgar & Edgarette: CARDIFF ONCOLOGY, INC. (CRDF) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/CRDF. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

